Navigation Links
Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)
Date:5/24/2010

SAN MARINO, Calif., May 24 /PRNewswire/ -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com) today announces the clinical results of the study entitled "A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol" at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.

SUMMARY: Rexin-G and Reximmune-C are tumor-targeted retrovectors bearing a cytocidal anti-cyclin G1 construct and a controllable GM-CSF expression construct, respectively. The working hypothesis underlying this two-tier complementary approach to tumor eradication and cancer vaccination is that a personalized vaccination of a patient against his or her own specific cancer can be achieved by combining (1) a targeted vector bearing a tumoricidal payload, i.e. Rexin-G, with (2) a targeted vector bearing a potent immuno-stimulatory (GM-CSF) gene, i.e. Reximmune-C. In this model, Rexin-G is first administered to control tumor growth and expose neoantigens within the tumor microenvironment, followed by defined pulses of Reximmune-C, intended to recruit the patient's immune cells into these lesions, thereby prompting immunologic activation, recognition of tumor neoantigens, and induction of a beneficial antitumor immunity. The initial results of a Phase I/II dose escalation study showed that, in addition to the expected tumoricidal effects of Rexin-G, histopathologic examination of biopsied tumors from patients with a diversity of cancer types revealed targeted nanoparticle delivery, GM-CSF transgene expression, and localized immune responses within the lesions. Importantly, no circulating GM-CSF protein was detected and no dose limiting toxicity was observed throughout the treatment period. Moreover, there appears to be a significant survival benefit which suggests that this two-tier approach has considerable merit as a therapeutic vaccine.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products, Rexin-G and Reximmune-C, and its high-performance gene delivery systems. To learn more about these agents and/or ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.

*(LOGO 72dpi: www.send2press.com/mediaboom/10-0504-epeiusbio_72dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
2. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
3. Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
4. Penn-led collaboration mimics library of bio-membranes for use in nanomedicine, drug delivery
5. BioSpec Global Solutions Inc, takes delivery of new TOGs 3000 Home edition for the U.S. and international markets
6. Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone
7. North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India
8. Micro shuttle drug delivery could mean an end to regular dosing
9. Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation
10. Bavarian Nordic Has Signed Contract With an EU Country for the Delivery of IMVAMUNE(R)
11. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... After her brain cancer ... gave her only a few months to live. Now a paper publishing January ... Rosendahl’s disease and increased both the quantity and quality of her life: Adding ...
(Date:1/12/2017)... Pune, India , January 12, 2017 A new ... Type and End Users - Global Opportunity Analysis and Industry Forecast, 2014-2022," projects that ... $2,921 million in 2015, growing at a CAGR of 15.07% during the forecast period. ... ... Market Research Logo ...
(Date:1/11/2017)... AURORA, Colo. (PRWEB) , ... January 11, 2017 ... ... in the journal Clinical Cancer Research show early promise of the investigational anti-cancer ... progressed despite a median 5 previous treatment regimens. Twenty-seven percent of these heavily ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... society for optics and photonics , are commending the U.S. Congress and President ... signing Friday by the President of the American Innovation and Competitiveness Act (AICA). ...
Breaking Biology Technology:
(Date:12/16/2016)... global wearable medical device market, in terms of value, is projected ... in 2016, at a CAGR of 18.0% during the forecast period. ... Growth in ... launch of a growing number of smartphone-based healthcare apps compatible with ... increasing focus on physical fitness. Furthermore, growing trend ...
(Date:12/15/2016)... ... Markets has announced the addition of the "Global Military Biometrics Market ... the global military biometrics market to grow at a CAGR of 7.5% ... based on an in-depth market analysis with inputs from industry experts. The ... years. The report also includes a discussion of the key vendors operating ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
Breaking Biology News(10 mins):